Your browser doesn't support javascript.
loading
A bibliometric analysis of PCSK9 inhibitors from 2007 to 2022.
Luo, Qin; Tang, Zhenchu; Wu, Panyun; Chen, Zhangling; Fang, Zhenfei; Luo, Fei.
  • Luo Q; Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Tang Z; Research Institute of Blood Lipid and Atherosclerosis, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Wu P; Department of Neurology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Chen Z; Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
  • Fang Z; Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Luo F; Research Institute of Blood Lipid and Atherosclerosis, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Front Endocrinol (Lausanne) ; 14: 1218968, 2023.
Article en En | MEDLINE | ID: mdl-38093957
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Proproteína Convertasa 9 / Inhibidores de PCSK9 Límite: Female / Humans País como asunto: America do norte Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Proproteína Convertasa 9 / Inhibidores de PCSK9 Límite: Female / Humans País como asunto: America do norte Idioma: En Año: 2023 Tipo del documento: Article